Kyverna Therapeutics
Clinical trials sponsored by Kyverna Therapeutics, explained in plain language.
-
Experimental CAR-T therapy takes on Hard-to-Treat lupus nephritis
Disease control OngoingThis early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 p…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Could CAR-T cells tame tough lupus kidney disease?
Disease control OngoingThis early-phase trial is testing a new treatment called KYV-101, which uses a patient's own modified immune cells (CAR-T cells) to target and destroy faulty B cells that drive lupus kidney inflammation. The study involves 6 adults with lupus nephritis that hasn't responded to st…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental CAR-T therapy takes aim at Hard-to-Treat scleroderma
Disease control OngoingThis early-phase trial is testing a new treatment called KYV-101 for people with systemic sclerosis, a disease where the immune system attacks the body, causing skin and organ damage. The therapy uses a patient's own modified immune cells to target and destroy certain B cells tha…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC